These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 32086656)

  • 41. Estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 status in invasive breast cancer: a 3,198 cases study at National Cancer Center, China.
    Zhu X; Ying J; Wang F; Wang J; Yang H
    Breast Cancer Res Treat; 2014 Oct; 147(3):551-5. PubMed ID: 25234844
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The Impact of Reproductive Factors on the Risk of Breast Cancer by ER/PR and HER2: A Multicenter Case-Control Study in Northern and Eastern China.
    Xie F; Liu L; Yang H; Liu M; Wang S; Guo J; Yu L; Zhou F; Wang F; Xiang Y; Yu Z; Wang S
    Oncologist; 2022 Feb; 27(1):e1-e8. PubMed ID: 35305101
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Menstrual and reproductive characteristics and breast cancer risk by hormone receptor status and ethnicity: The Breast Cancer Etiology in Minorities study.
    John EM; Phipps AI; Hines LM; Koo J; Ingles SA; Baumgartner KB; Slattery ML; Wu AH
    Int J Cancer; 2020 Oct; 147(7):1808-1822. PubMed ID: 32064598
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Breast cancer-specific survival by clinical subtype after 7 years follow-up of young and elderly women in a nationwide cohort.
    Johansson ALV; Trewin CB; Hjerkind KV; Ellingjord-Dale M; Johannesen TB; Ursin G
    Int J Cancer; 2019 Mar; 144(6):1251-1261. PubMed ID: 30367449
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Everolimus plus Exemestane for Hormone Receptor-Positive Advanced Breast Cancer: A PAM50 Intrinsic Subtype Analysis of BOLERO-2.
    Prat A; Brase JC; Cheng Y; Nuciforo P; Paré L; Pascual T; Martínez D; Galván P; Vidal M; Adamo B; Hortobagyi GN; Baselga J; Ciruelos E
    Oncologist; 2019 Jul; 24(7):893-900. PubMed ID: 30679318
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Long-Term Outcomes of Immunohistochemically Defined Subtypes of Breast Cancer Less Than or Equal to 2 cm After Breast-Conserving Surgery.
    Pata G; Guaineri A; Bianchi A; Amoroso V; Pasinetti N; Pasini M
    J Surg Res; 2019 Apr; 236():288-299. PubMed ID: 30694768
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clinical subtypes and prognosis of pregnancy-associated breast cancer: results from the Korean Breast Cancer Society Registry database.
    Bae SY; Kim SJ; Lee J; Lee ES; Kim EK; Park HY; Suh YJ; Kim HK; You JY; Jung SP
    Breast Cancer Res Treat; 2018 Nov; 172(1):113-121. PubMed ID: 30088177
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Impact of molecular subtypes classification concordance between preoperative core needle biopsy and surgical specimen on early breast cancer management: Single-institution experience and review of published literature.
    Meattini I; Bicchierai G; Saieva C; De Benedetto D; Desideri I; Becherini C; Abdulcadir D; Vanzi E; Boeri C; Gabbrielli S; Lucci F; Sanchez L; Casella D; Bernini M; Orzalesi L; Vezzosi V; Greto D; Mangoni M; Bianchi S; Livi L; Nori J
    Eur J Surg Oncol; 2017 Apr; 43(4):642-648. PubMed ID: 27889196
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
    Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
    Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Diet quality indices are associated with breast cancer by molecular subtypes in Mexican women.
    Armenta-Guirado BI; Mérida-Ortega Á; López-Carrillo L; Denova-Gutiérrez E
    Eur J Nutr; 2024 Dec; 63(8):3223-3233. PubMed ID: 39325098
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Breast cancer recurrence according to molecular subtype.
    Shim HJ; Kim SH; Kang BJ; Choi BG; Kim HS; Cha ES; Song BJ
    Asian Pac J Cancer Prev; 2014; 15(14):5539-44. PubMed ID: 25081661
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Risk factors for HR- and HER2-defined breast cancer in Slovenian postmenopausal women.
    Cerne JZ; Ferk P; Frkovic-Grazio S; Leskosek B; Gersak K
    Climacteric; 2012 Feb; 15(1):68-74. PubMed ID: 22132797
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Is breast cancer from Sub Saharan Africa truly receptor poor? Prevalence of ER/PR/HER2 in breast cancer from Kenya.
    Sayed S; Moloo Z; Wasike R; Bird P; Oigara R; Govender D; Kibera J; Carrara H; Saleh M
    Breast; 2014 Oct; 23(5):591-6. PubMed ID: 25012047
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Reproductive profiles and risk of breast cancer subtypes: a multi-center case-only study.
    Brouckaert O; Rudolph A; Laenen A; Keeman R; Bolla MK; Wang Q; Soubry A; Wildiers H; Andrulis IL; Arndt V; Beckmann MW; Benitez J; Blomqvist C; Bojesen SE; Brauch H; Brennan P; Brenner H; Chenevix-Trench G; Choi JY; Cornelissen S; Couch FJ; Cox A; Cross SS; Czene K; Eriksson M; Fasching PA; Figueroa J; Flyger H; Giles GG; González-Neira A; Guénel P; Hall P; Hollestelle A; Hopper JL; Ito H; Jones M; Kang D; ; Knight JA; Kosma VM; Li J; Lindblom A; Lilyquist J; Lophatananon A; Mannermaa A; Manoukian S; Margolin S; Matsuo K; Muir K; Nevanlinna H; Peterlongo P; Pylkäs K; Saajrang S; Seynaeve C; Shen CY; Shu XO; Southey MC; Swerdlow A; Teo SH; Tollenaar RAEM; Truong T; Tseng CC; van den Broek AJ; van Deurzen CHM; Winqvist R; Wu AH; Yip CH; Yu JC; Zheng W; Milne RL; Pharoah PDP; Easton DF; Schmidt MK; Garcia-Closas M; Chang-Claude J; Lambrechts D; Neven P
    Breast Cancer Res; 2017 Nov; 19(1):119. PubMed ID: 29116004
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Hormone receptor and HER2 status in patients with breast cancer by races in southeastern Turkey.
    Kuzhan A; Adli M; Eryigit Alkis H; Caglayan D
    J BUON; 2013; 18(3):619-22. PubMed ID: 24065473
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Heterogeneity of breast cancer subtypes and survival among Hispanic women with invasive breast cancer in California.
    Banegas MP; Tao L; Altekruse S; Anderson WF; John EM; Clarke CA; Gomez SL
    Breast Cancer Res Treat; 2014 Apr; 144(3):625-34. PubMed ID: 24658879
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Chemotherapy response and survival of inflammatory breast cancer by hormone receptor- and HER2-defined molecular subtypes approximation: an analysis from the National Cancer Database.
    Liu J; Chen K; Jiang W; Mao K; Li S; Kim MJ; Liu Q; Jacobs LK
    J Cancer Res Clin Oncol; 2017 Jan; 143(1):161-168. PubMed ID: 27704268
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Distinct Reproductive Risk Profiles for Intrinsic-Like Breast Cancer Subtypes: Pooled Analysis of Population-Based Studies.
    Jung AY; Ahearn TU; Behrens S; Middha P; Bolla MK; Wang Q; Arndt V; Aronson KJ; Augustinsson A; Beane Freeman LE; Becher H; Brenner H; Canzian F; Carey LA; ; Czene K; Eliassen AH; Eriksson M; Evans DG; Figueroa JD; Fritschi L; Gabrielson M; Giles GG; Guénel P; Hadjisavvas A; Haiman CA; Håkansson N; Hall P; Hamann U; Hoppe R; Hopper JL; Howell A; Hunter DJ; Hüsing A; Kaaks R; Kosma VM; Koutros S; Kraft P; Lacey JV; Le Marchand L; Lissowska J; Loizidou MA; Mannermaa A; Maurer T; Murphy RA; Olshan AF; Olsson H; Patel AV; Perou CM; Rennert G; Shibli R; Shu XO; Southey MC; Stone J; Tamimi RM; Teras LR; Troester MA; Truong T; Vachon CM; Wang SS; Wolk A; Wu AH; Yang XR; Zheng W; Dunning AM; Pharoah PDP; Easton DF; Milne RL; Chatterjee N; Schmidt MK; García-Closas M; Chang-Claude J
    J Natl Cancer Inst; 2022 Dec; 114(12):1706-1719. PubMed ID: 35723569
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The relevance of intrinsic subtype to clinicopathological features and prognosis in 4,266 Japanese women with breast cancer.
    Shibuta K; Ueo H; Furusawa H; Komaki K; Rai Y; Sagara Y; Kamada Y; Tamaki N
    Breast Cancer; 2011 Oct; 18(4):292-8. PubMed ID: 20571962
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Breast cancer subtypes as defined by the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) among women with invasive breast cancer in California, 1999-2004.
    Parise CA; Bauer KR; Brown MM; Caggiano V
    Breast J; 2009; 15(6):593-602. PubMed ID: 19764994
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.